High-dimensional neural ODE model to characterize clinical pharmacokinetics of MMAE-based antibody-drug conjugates

This study investigates Neural ordinary differential equation (NODE) model to describe clinical pharmacokinetic (PK) data from Monomethyl auristatin E (MMAE)-based antibody-drug conjugates (ADCs). ADC PK is composed of four analytes: total antibody (tmAbs), antibody-conjugated MMAE, unconjugated free MMAE (fMMAE), and ADC. Two different model architectures were explored, one that predicts single-state with one NODE model (single-state NODE) and the other that predicts all states with one single NODE model (multiple-states NODE). All the models were trained with single-dose regimen PK datasets at dose levels of 0.1, 0.5, 1.0, 1.8, 2.4 mg/kg. After training, the models could extrapolate to unseen single-dose regimen datasets at dose levels of 0.15 to 3.3 mg/kg and multiple-dose regimen datasets at dose levels of 0.3 to 3.0 mg/kg with various dosing frequencies (Q1W and Q3W) without introducing covariates such as inter-product variability or inter-study variability. The final model performance, assessed as percent prediction error (%PE) was acceptable. For single-state NODE, the average pooled %PE values across studies were 9.4, -11, 6.6, and 40 for total antibodies, antibody-conjugated MMAE, free MMAE, and ADC, respectively. For multiple-states NODE, the average pooled %PE values across studies were 5.2, -14, 17, and 31 for total antibodies, antibody-conjugated MMAE, free MMAE, and ADCs, respectively. The training process and good training practices for a NODE model development and the limitations of the current model were discussed. This study provides proof of concept for training a NODE model on high-dimensional, highly variable real-world PK data.

Authors

Institutions

Publication Details

Journal
Journal of Pharmacokinetics and Pharmacodynamics
Published
2026-11-17
DOI
https://doi.org/10.1007/s10928-026-10072-5
Primary Topic
Monoclonal and Polyclonal Antibodies Research
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

High-dimensional neural ODE model to characterize clinical pharmacokinetics of MMAE-based antibody-drug conjugates

Anne T. A. Nguyen, Dominic Stefan Bräm, Dhaval K. Shah, Hsien Wei Huang et al.
5 links
Journal of Pharmacokinetics and Pharmacodynamics
Monoclonal and Polyclonal Antibodies Research
article

High-dimensional neural ODE model to characterize clinical pharmacokinetics of MMAE-based antibody-drug conjugates

Anne T. A. Nguyen, Dominic Stefan Bräm, Dhaval K. Shah, Hsien Wei Huang, Hsuan-Ping Chang, Raphael Ghobrial
article en

Abstract

This study investigates Neural ordinary differential equation (NODE) model to describe clinical pharmacokinetic (PK) data from Monomethyl auristatin E (MMAE)-based antibody-drug conjugates (ADCs). ADC PK is composed of four analytes: total antibody (tmAbs), antibody-conjugated MMAE, unconjugated free MMAE (fMMAE), and ADC. Two different model architectures were explored, one that predicts single-state with one NODE model (single-state NODE) and the other that predicts all states with one single NODE model (multiple-states NODE). All the models were trained with single-dose regimen PK datasets at dose levels of 0.1, 0.5, 1.0, 1.8, 2.4 mg/kg. After training, the models could extrapolate to unseen single-dose regimen datasets at dose levels of 0.15 to 3.3 mg/kg and multiple-dose regimen datasets at dose levels of 0.3 to 3.0 mg/kg with various dosing frequencies (Q1W and Q3W) without introducing covariates such as inter-product variability or inter-study variability. The final model performance, assessed as percent prediction error (%PE) was acceptable. For single-state NODE, the average pooled %PE values across studies were 9.4, -11, 6.6, and 40 for total antibodies, antibody-conjugated MMAE, free MMAE, and ADC, respectively. For multiple-states NODE, the average pooled %PE values across studies were 5.2, -14, 17, and 31 for total antibodies, antibody-conjugated MMAE, free MMAE, and ADCs, respectively. The training process and good training practices for a NODE model development and the limitations of the current model were discussed. This study provides proof of concept for training a NODE model on high-dimensional, highly variable real-world PK data.

Journal of Pharmacokinetics and PharmacodynamicsVol. 53(6)
University of Basel (CH), University Children’s Hospital Basel (CH), University at Buffalo, State University of New York (US)
National Cancer Institute, National Institute of General Medical Sciences, National Institute of Allergy and Infectious Diseases, National Institute of Child Health and Human Development, Center for Protein Therapeutics, University at Buffalo
Good health and well-being
Monoclonal and Polyclonal Antibodies Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon